New York is currently home to 4462 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Recruiting
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: SUNY-Stony Brook, Stony Brook, New York
Conditions: COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
Recruiting
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoin... Read More
Gender:
ALL
Ages:
39 years and below
Trial Updated:
03/10/2025
Locations: New York Medical College, Vallhala, New York
Conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Recruiting
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York
Conditions: Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary, Advanced Mycosis Fungoides
Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients with Epilepsy Involving the Temporal Lobe Region.
Recruiting
The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region . 2-5 sites in Europe Up to 10 sites in U... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/10/2025
Locations: Northwell Health Department of Neurosurgery, Great Neck, New York
Conditions: Epilepsy
Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Recruiting
This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York
Conditions: B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
03/10/2025
Locations: Mount Sinai Queens, Astoria, New York
Conditions: Breast Cancer
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
Recruiting
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once week... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/10/2025
Locations: Kings Country Hospital Center, Brooklyn, New York
Conditions: HSV Infection
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Recruiting
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/10/2025
Locations: Northwell Health System, Manhasset, New York
Conditions: Venous Thromboembolism
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Recruiting
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
03/10/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
The Cancer of the Pancreas Screening-5 CAPS5)Study
Recruiting
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
Recruiting
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
03/09/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients
Recruiting
Patients with heart failure (HF) represent a large population of patients who are at high risk for complications related to undiagnosed atrial fibrillation (AF). However, currently there are limited modalities for early AF detection and subsequent stroke prevention in this high-risk population. An implantable cardiac monitor (ICM) is inserted subcutaneously and can provide long term arrhythmia information via remote monitoring. The ASSERT-AF study seeks to accurately define the burden of AF and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atrial Fibrillation, Heart Failure